Surgery – Miscellaneous – Methods
Patent
1997-12-08
2000-11-28
Millin, V.
Surgery
Miscellaneous
Methods
604 4, 604 96, A61B 1900
Patent
active
061521418
ABSTRACT:
A method for delivering a therapeutic agent directly to the heart employing minimally invasive techniques and concepts. In particular, the delivery of vascular endothelial growth factors (VEGF) is performed endovascularly or endoscopically to a region of a patient's heart treated with transmyocardial revascularization (TMR). A system is provided for inducing cardioplegic arrest. An aortic occlusion device has an inflatable balloon which occludes the ascending aorta when inflated. Cardioplegic fluid may be infused through a lumen of the aortic occlusion device to stop the heart while the patient's circulatory system is supported on cardiopulmonary bypass. A side-firing fiberoptic laser is introduced through the aortic occlusion device in the endovascular technique to perform TMR. Subsequently, a therapeutic agent delivery catheter is directed into one of the coronary arteries to deliver and dissipate the VEGF into the surrounding vascular plexus to promote angiogenesis stimulation. Alternatively, a therapeutic agent delivery material saturated or coated with VEGF could be sutured to the epicardial surface of the heart, using thoracoscopic techniques, for timed release delivery of the agent to the TMR treated site.
REFERENCES:
patent: Re35352 (1996-10-01), Peters
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5279565 (1994-01-01), Klein et al.
patent: 5298487 (1994-03-01), Chen et al.
patent: 5312344 (1994-05-01), Grinfeld et al.
patent: 5318957 (1994-06-01), Cid et al.
patent: 5330498 (1994-07-01), Hill
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5336178 (1994-08-01), Kaplan et al.
patent: 5336518 (1994-08-01), Narayanan et al.
patent: 5354279 (1994-10-01), Hofling
patent: 5370685 (1994-12-01), Stevens
patent: 5419777 (1995-05-01), Hofling
patent: 5425705 (1995-06-01), Evard et al.
patent: 5433700 (1995-07-01), Peters
patent: 5452733 (1995-09-01), Sterman et al.
patent: 5458574 (1995-10-01), Machold et al.
patent: 5478309 (1995-12-01), Sweezer et al.
patent: 5499996 (1996-03-01), Hill
patent: 5501698 (1996-03-01), Roth et al.
patent: 5505701 (1996-04-01), Anaya Fernandez de Lomana
patent: 5522838 (1996-06-01), Hill
patent: 5533516 (1996-07-01), Sahatjian
patent: 5536251 (1996-07-01), Evard et al.
patent: 5545214 (1996-08-01), Stevens
patent: 5549674 (1996-08-01), Humes et al.
patent: 5556412 (1996-09-01), Hill
patent: 5558644 (1996-09-01), Boyd et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5569274 (1996-10-01), Rapacki et al.
patent: 5571215 (1996-11-01), Sterman et al.
patent: 5575815 (1996-11-01), Slepian et al.
patent: 5580722 (1996-12-01), Foulkes et al.
patent: 5584803 (1996-12-01), Stevens et al.
patent: 5586982 (1996-12-01), Abela
patent: 5588962 (1996-12-01), Nicholas et al.
patent: 5591197 (1997-01-01), Orth et al.
patent: 5599306 (1997-02-01), Klein et al.
patent: 5618307 (1997-04-01), Donlon et al.
patent: 5626607 (1997-05-01), Malecki et al.
patent: 5634895 (1997-06-01), Igo et al.
patent: 5682906 (1997-11-01), Sterman et al.
patent: 5695457 (1997-12-01), St. Goar et al.
patent: 5702368 (1997-12-01), Stevens et al.
patent: 5718725 (1998-02-01), Sterman et al.
patent: 5885238 (1999-03-01), Stevens et al.
Brown et al., "Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor," The New England Journal of Medicine, 1989;321(2):76-79.
Burkhoff et al., "Histologic Appearance of Transmyocardial Laser Channels After 41/2 Weeks," Ann Thorac Surg, 1996;61:1532-1535.
Cooley et al., "Transmyocardial Laser Revascularization: Clinical Experience with Twelve-month Follow-up," J Thorac Card Surg, 1996;111(4):791-799.
Engler, "Use of Vascular Endothelial Growth Factor Angiogenesis," Circulation, 1996;94(7):1496-1498.
Fasol et al., "Experimental Use of a Modified Fibrin Glue to Induce Site-directed Angiogenesis from the Aorta to the Heart," J Thorac Card Surg, 1994;107(6):1432-1439.
Fleischer et al., "One-month Histologic Response of Transmyocardial Laser Channels with Molecular Intervention," Ann Thorac Surg, 1996;62:1051-1058.
Folkman and Klagsbrun, "Angiogenic Factors," Science, 1987;235:442-447.
Hockel et al., "Therapeutic Angiogenesis," Arch Surg, 1993;128:423-429.
Horvath et al., "Transmyocardial Laser Revascularization: Operative Techniques and Clinical Results at Two Years," J Thorac Card Surg, 1996;111(5):1047-1053.
Isner et al., "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients with Peripheral Artery Disease," Circulation, 1995;91(11):2687-2692.
Kissel et al., "Parental Depot-systems on the Basis of Biodegradable Polyesters," Journal of Controlled Substances, 1991;16:27-41.
Langer, "New Methods of Drug Delivery," Science, 1990;249:1527-1533.
Langer and Moses, "Biocompatible Controlled Release Polymers for Delivery of Polypeptides and Growth Factors," Journal of Cellular Biochemistry, 1991;45:340-345.
Kohmoto et al., "Does Blood Flow Through Holmium; YAG Transmyocardial Laser Channels?" Ann Thorac Surg, 1996;61:861-868.
Rawlins, "Adverse Effects of Novel Delivery Systems," Novel Drug Delivery and Its Theapeutic Application, Chapter 22, pp. 237-243.
Smith et al., Transmyocardial Laser Revasculariztion, J Card Surg, 1995;10:569-572.
Tice et al., "Clinical Use and Future of Parental Microsphere Delivery Systems," Novel Drug Delivery and It's Therapeutic Application, Chapter 21, pp. 223-235.
Weatherford et al., "Vascular Endothelial Growth Factor and Heparin in a Biologic Glue Promotes Human Aortic Endothelial Cell Proliferation with Aortic Smooth Muscle Cell Inhibition," Surgery, 1996;120(2):433-439.
Brewer Richard B.
Gifford, III Hanson S.
Rosenman Daniel C.
Stevens John H.
Heartport Inc.
Hoekendijk Jens E.
Lynch Michael J.
Millin V.
O'Hara Kelly
LandOfFree
Method for delivery of therapeutic agents to the heart does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for delivery of therapeutic agents to the heart, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for delivery of therapeutic agents to the heart will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1714781